Alpha 2.0
Login Register
» Authors » Kristi A Boehm

Kristi A Boehm

Explore the profile of Kristi A Boehm including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 36
Citations 859
Followers 0
Related Specialties
Oncology
Urology
Pharmacology
Top 10 Co-Authors
Lina Asmar
Feng Zhan
Donald A Richards
Craig Reynolds
Des Ilegbodu
Joanne L Blum
William R Berry
Nicholas Di Bella
Thomas Cartwright
Svetislava J Vukelja
Published In
J Clin Oncol
Clin Genitourin Cancer
Invest New Drugs
Clin Colorectal Cancer
Clin Ther
Affiliations
Soon will be listed here.
Recent Articles
1.
Results of two Phase 1, Randomized, Double-blind, Placebo-controlled, Studies (Ascending Single-dose and Multiple-dose Studies) to Determine the Safety, Tolerability, and Pharmacokinetics of Orally Administered LX9211 in Healthy Participants
Bundrant L, Hunt T, Banks P, Gopinathan S, Boehm K, Kassler-Taub K, et al.
Clin Ther . 2021 Jun; 43(6):1029-1050. PMID: 34108079
Purpose: For neuropathic pain, current therapies do not provide relief for most patients; less than half achieve a 50% pain reduction. Current analgesics have adverse effects. We present 2 Phase...
2.
Patient-reported Symptom Experiences in Patients With Carcinoid Syndrome After Participation in a Study of Telotristat Etiprate: A Qualitative Interview Approach
Gelhorn H, Kulke M, ODorisio T, Yang Q, Jackson J, Jackson S, et al.
Clin Ther . 2016 Apr; 38(4):759-68. PMID: 27041406
Purpose: Telotristat etiprate, a tryptophan hydroxylase inhibitor, was previously evaluated in a Phase II randomized, placebo-controlled clinical trial in patients with carcinoid syndrome (CS) and diarrhea not adequately controlled by...
3.
Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects
Zambrowicz B, Ogbaa I, Frazier K, Banks P, Turnage A, Freiman J, et al.
Clin Ther . 2013 Aug; 35(8):1162-1173.e8. PMID: 23911260
Background: LX4211 is a first-in-class dual inhibitor of sodium-dependent glucose cotransporters 1 and 2 (SGLT1 and SGLT2). SGLT1 is the primary transporter for glucose absorption from the gastrointestinal tract, and...
4.
Sunitinib malate in previously untreated, nonsquamous, non-small cell lung cancer patients over the age of 70 years: results of a Phase II trial
Reynolds C, Spira A, Gluck L, Bradie-Muller S, Mueller S, Zhan F, et al.
Invest New Drugs . 2013 Jun; 31(5):1330-8. PMID: 23761052
Background: Some elderly patients may have reduced tolerance the standard therapy (chemotherapy doublets) for stage III/IV non-small cell lung cancer (NSCLC). Sunitinib malate (S), an oral, multitargeted kinase inhibitor, shows...
5.
Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer
Fleming M, Sonpavde G, Kolodziej M, Awasthi S, Hutson T, Martincic D, et al.
Clin Genitourin Cancer . 2012 Feb; 10(1):6-14. PMID: 22340631
Purpose: Cetuximab (C), a chimeric monoclonal antibody that binds epidermal growth factor receptor (EGFR), is active against androgen-independent prostate cancer cell lines and might enhance the activity of chemotherapy. The...
6.
A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer
Carter D, Garfield D, Hathorn J, Mundis R, Boehm K, Ilegbodu D, et al.
Clin Lung Cancer . 2011 Dec; 13(3):205-13. PMID: 22138037
Background: This study was designed to determine the efficacy and safety of additional maintenance chemotherapy after standard induction chemotherapy/radiation therapy (XRT) in stage III non-small-cell lung cancer (NSCLC). The primary...
7.
Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer
Saltz L, Badarinath S, Dakhil S, Bienvenu B, Harker W, Birchfield G, et al.
Clin Colorectal Cancer . 2011 Nov; 11(2):101-11. PMID: 22055112
Background: Cetuximab (C), alone or with irinotecan, demonstrates activity in irinotecan-refractory colorectal cancer (CRC). Activity of 5-fluorouracil (5-FU), leucovorin (L), and bevacizumab (B), and preliminary data of cetuximab + bevacizumab,...
8.
A Phase III trial of fludarabine, cyclophosphamide, and rituximab vs. pentostatin, cyclophosphamide, and rituximab in B-cell chronic lymphocytic leukemia
Reynolds C, Di Bella N, Lyons R, Hyman W, Richards D, Robbins G, et al.
Invest New Drugs . 2011 Sep; 30(3):1232-40. PMID: 21922186
Background: Uncontrolled studies comparing pentostatin (P), cyclophosphamide (C), and rituximab (R) (PCR) to fludarabine plus C+R (FCR) suggest similar efficacy with fewer infectious complications with PCR. We compared FCR and...
9.
A phase II open-label trial of bortezomib in patients with multiple myeloma who have undergone an autologous peripheral blood stem cell transplant and failed to achieve a complete response
Rifkin R, Greenspan A, Schwerkoske J, Mandanas R, Stephenson J, Kannarkat G, et al.
Invest New Drugs . 2010 Oct; 30(2):714-22. PMID: 20938715
Background: A majority of multiple myeloma (MM) patients fail to achieve complete response (CR) to peripheral blood stem cell transplantation (PBSCT); effective options following autologous transplantation are needed. Bortezomib (B)...
10.
Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma
Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F, et al.
Clin Lymphoma Myeloma Leuk . 2010 Jun; 10(3):186-91. PMID: 20511163
Background: Filgrastim decreases the time to neutrophil recovery after autologous peripheral blood stem cell transplantation (PBSCT). We hypothesized that single-dose pegfilgrastim would mimic multiple daily doses of filgrastim, resulting in...